Paul A. Meyers, MD
Chief, Pediatric Sarcoma Service; Vice Chair for Clinical Affairs
Pediatric Oncology; Osteosarcoma; Ewing Sarcoma; Leukemias; Rhabdomyosarcoma and Other Soft Tissue Developmental Tumors of Childhood
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Meyers accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans and Medicare plans. Emblem Health does not include us in any of its Select Care network plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Mount Sinai School of Medicine
Pediatrics - Mount Sinai Hospital
Pediatrics - Cornell Medical Center; Pediatrics - Memorial Sloan Kettering Cancer Center
Pediatrics; Pediatric Hematology-Oncology
I am a pediatric oncologist with extensive experience caring for children and young adults with sarcomas. At Memorial Sloan Kettering, we treat more children and young adults with these challenging tumors than anywhere else in the country. I am proud to be part of MSK Kids, a team that takes a comprehensive approach to care. We customize a care plan for each child, with the goal of saving the lives of our young patients.
Many of our patients are teens and young adults. They are transitioning from childhood dependence on their parents to independent living. We help them maintain their independence in every way during their cancer care while still ensuring that they have the emotional and practical support of their family.
Many of the types of cancer in young adults are quite rare. Very few oncologists have experience treating them. Some young adults have a form of cancer that is seen much more commonly in children and teens. These patients need a team of specialists from multiple medical fields. They can find that level of expertise in the multidisciplinary teams at Memorial Sloan Kettering. Our specialists combine their skills and experience to come up with the most effective therapy for each individual.
I also direct clinical research to develop and assess new therapies for sarcomas. For five years I served as head of the bone sarcoma strategy group for the Children’s Cancer Group. In that role, I directed national clinical trials for osteosarcoma and Ewing sarcoma. I also conducted clinical trials for people with newly diagnosed and recurrent osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma, undifferentiated sarcoma, and other unusual tumors that occur in children and young adults. I have much more experience treating these challenging cancers than most doctors.
In addition to caring for patients and doing research, I enjoy teaching. Memorial Sloan Kettering offers one of the most comprehensive training programs in pediatric hematology/oncology in the country. We care for a very large number of patients, and our faculty has many decades of experience. Our trainees see an unparalleled variety of clinical challenges. Fellows also have the benefit of working with faculty at nearby institutions, such as Weill Cornell Medicine and The Rockefeller University.
I have authored or co-authored more than 135 publications about sarcomas. In recognition of my work, I received the Willet E. Whitmore Award for Clinical Excellence from Memorial Sloan Kettering in 1995. I served as president of the Connective Tissue Oncology Society, a leading academic society devoted to the study of sarcomas. I am a member of the National Cancer Institute’s Physician Data Query Pediatric Board.
I am also the founding medical director for Happiness Is Camping, a summer camp for children with cancer. Helping give these kids a respite from the rigors of cancer therapy has been an extraordinary opportunity. To see these children blossom and thrive away from the hospital environment is one of the great joys of my job.
I am proud to be part of MSK Kids, a team that takes a comprehensive approach to care.
Awards and Honors
- Castle Connolly: New York Magazine Top Doctors (2002-2018)
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
- Clinical Trials Investigated by Dr. Meyers
- A Phase I Study of Seclidemstat (SP-2577) with and without Topotecan and Cyclophosphamide in Patients with Recurrent or Persistent Ewing Sarcoma and Other Select Sarcomas
- A Phase I Study of TK216 in Patients with Recurrent or Persistent Ewing Sarcoma
- A Phase II Study of Irinotecan and Temozolomide in Combination with Existing High-Dose Chemotherapy for Patients Newly Diagnosed with Ewing Sarcoma
- Clinical Trials Co-Investigated by Dr. Meyers
- A Phase I/II Study of LOXO-101 in Children with Infantile Fibrosarcoma, Primary Brain Tumors, and Other Advanced Solid Tumors
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan Kettering experience and a literature review.. J Clin Oncol. 2001; 19 :870-880
Shamberger RC, Laquaglia MP, Krailo MD, Miser JS, Pritchard DJ, Gebhardt MC, Healey JH, Tarbell NJ, Fryer CJ, Meyers PA, Grier HE.. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection.. J Thorac Cardiovasc Surg. 2000; 119 :1154-61
Kushner BH, Heller G, Cheung NK, Wollner N, Kramer K, Bajorin D, Polyak T, Meyers PA.. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.. J Clin Oncol 1998; 16 :3016-20
Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH.. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma.. J Bone Joint Surg Am. 1998; 80 :1020-33
Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH.. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan Kettering (T12) protocol.. J Clin Oncol 1998; 16 :2452-8
de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, Gerald WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PH, Barr FG, Ladanyi M.. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing sarcoma. J Clin Oncol 1998; 16 :1248-55
Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, Huvos AG, Larson SM.. Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, Huvos AGThallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma, Larson SM.. Cancer 1997; 80 :1507-12
O’Reilly R, Link M, Fletcher B, Gebhardt M, Krance R, Meyers P, Neff J, Schwartz C.. NCCN pediatric osteosarcoma practice guidelines. The National Comprehensive Cancer Network.. Oncology 1996; 10 :1799-806
Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, Crouch G, Kelleher JF Jr, Steinherz PG, Gerald WL.. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy.. J Clin Oncol 1996; 14 :1526-31
Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, et al.. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing sarcoma, in children and young adults. J Clin Oncol 1995; 13 :2796-804
Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, et al.. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma.. N Engl J Med 1992; 326 :1301-8
Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G.. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan Kettering experience. J Clin Oncol 1992; 10 :5-15
Visit PubMed for a full listing of Dr. Meyers’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Paul A. Meyers discloses the following relationships and financial interests:
Provision of Services (uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.